The first biopsy was obtained when the patient had very active muscle disease and the second biopsy was obtained when the patient had minimal myositis activity, 5 months after starting a JAK/STAT inhibitor (i.e., tofacitinib). This evidence concerns the gene SOAT1 and myositis disease.